Alternatively, anti-PD-L1 ICIs (Durvalumab, Atezolizumab, Avelumab) target increased PD-L1 expression on DCs, macrophages, T and B cells, and tumor and endothelial cells. This evidence concerns the gene CD274 and neoplasm.